Andrew Sinclair is listed as a director on 3 SEC Form D filings by 3 issuers between Jul 2020 and Nov 2024: Verona Pharma plc (London, United Kingdom (as filed: X0) — pharmaceuticals — 2020; $200.2M reported sold to 43 investors), ASCEND ADVANCED THERAPIES GROUP, INC. (Alachua, FL — industry reported as "Other" — 2024; $130.6M reported sold to 9 investors) and Ascend Gene & Cell Therapies Ltd. (Altrincham, United Kingdom (as filed: X0) — industry reported as "Other" — 2023; $66.6M reported sold to 10 investors).
What this means A repeat sponsor — 3 separate companies raised money with this person listed as director, over about 4 years. Across those companies the filings report $397.4M sold in total.
Listed alongside BALAJI MURALIDHAR (2 shared filings), Fred Cohen (2 shared filings), Michael Beecham (2 shared filings), Timothy Funnell (2 shared filings), Anders Ullman (1 shared filing) and 18 others.
What this means These are the other officers, directors or promoters the companies named on the same forms — the team around Andrew. Each name links to their own page.
Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AZ, CA, DE, TX, WA) — 3 bankruptcy cases matching the name listed in Key records below.
What this means 3 records came back. Each one is listed below with a link to the original document and a line saying why it matched. A name match is not proof it is the same person or company — read the why line and the document. Being sued or named in a release is an accusation, not a finding.
We compared 3 public filings for Andrew Sinclair and found 6 differences: Form D filed 22 days after the first sale; Same name, different state: "Andrew Sinclair" (MA) is a separate record; and more below.
What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.